Angio Seal VIP Vascular Closure Device
Terumo Medical Corporation · Decision date Aug 4, 2026
What did the FDA approve?
FDA records P930038/S107 as a supplement to PMA P930038, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Aug 4, 2026.
FDA approval order statement
the addition of a new U.S. farm and a new USDA-registered abattoir for collagen
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 4, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P930038/S107
- Regulatory pathway
- PMA supplement
- Applicant
- Terumo Medical Corporation
- Product code
- MGB
- Decision code
- APPR
- Decision date
- Aug 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, hemostasis, vascular.
- Applicant
- Terumo Medical Corporation
- Product code
- MGB
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P930038/S106 · Related supplement
Angio-Seal Vascular Closure Device
P930038/S107 received
Application receipt date recorded by FDA.
P930038/S107 · FDA decision
135 Review Track For 30-Day Notice
Timeline entries are records held by MedtechLedger for P930038. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P930038
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Angio-Seal Vascular Closure DeviceP930038/S106 | Terumo Medical Corporation | PMA supplement | Aug 7, 2025 | FDA |
Explore the linked device profile
Other records with product code MGB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
CELT ACD VASCULAR CLOSURE DEVICEP150006/S009 | Vasorum, Ltd. | PMA supplement | Oct 30, 2026 | FDA |
| Abbott Vascular, Inc. | PMA supplement | Oct 26, 2026 | FDA | |
| Vivasure Medical , Ltd. | PMA approval | Oct 16, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Terumo Medical Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 950 Elkton Blvd., Elkton, MD, 21921
Sources and methodology
- Original FDA record: P930038/S107
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



